Cubist Systematic Strategies LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)

Cubist Systematic Strategies LLC grew its position in shares of Rezolute, Inc. (NASDAQ:RZLT) by 366.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,237 shares of the company’s stock after buying an additional 42,597 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Rezolute were worth $233,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in RZLT. Jeppson Wealth Management LLC purchased a new stake in Rezolute in the second quarter worth approximately $45,000. Virtu Financial LLC purchased a new stake in Rezolute in the first quarter worth approximately $37,000. XTX Topco Ltd boosted its holdings in Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Rezolute in the second quarter worth approximately $255,000. Finally, Acadian Asset Management LLC purchased a new stake in Rezolute in the first quarter worth approximately $229,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Price Performance

Shares of RZLT stock opened at $4.78 on Tuesday. The company has a market capitalization of $191.85 million, a price-to-earnings ratio of -4.19 and a beta of 1.19. Rezolute, Inc. has a one year low of $0.72 and a one year high of $6.10. The company’s fifty day moving average price is $4.69 and its 200-day moving average price is $4.06.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Equities research analysts expect that Rezolute, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RZLT has been the topic of several research reports. Maxim Group raised their target price on shares of Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 6th. BTIG Research increased their price target on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Guggenheim initiated coverage on shares of Rezolute in a research report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Rezolute in a research report on Friday, September 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Friday, September 27th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.